[Reboxetine (Edronax)].
Reboxetine is a new antidepressant acting by selective inhibition of noradrenaline reuptake (NARI) at the synaptic cleft. The efficacy of reboxetine is similar to other antidepressants such as tricyclic and Selective Serotonin reuptake inhibitors once (SSRI). A faster onset of action (in a mean of 10 days) is suggested by preliminary studies. Reboxetine seems also to improve social adjustment of the treated depressed patients. Due to its selectivity, reboxetine presents a favourable safety profile. Treatment of depression will certainly benefit from this new compound. However, some issues need to be clarified such as the use of reboxetine in combination with other antidepressants.
Souery
D
D
Service de Psychiatrie, Hôpital Erasme, U.L.B.
Sternon
J
J
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy / Q000523:psychology; D004338:Drug Combinations; D004347:Drug Interactions; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077593:Reboxetine; D012449:Safety; D012917:Social Adjustment; D013997:Time Factors
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D004338:Drug Combinations; D009025:Morpholines; D000077593:Reboxetine